Cargando…
Value of Perampanel as Adjunctive Treatment for Partial-Onset Seizures in Epilepsy: Cost-Effectiveness and Budget Impact Analysis
Introduction: China has ~6 million patients with active epilepsy every year, around 60% of whom suffer from partial-onset seizures. Perampanel (PER) is a novel anti-epileptic drug for partial-onset seizures. PER has been included in the latest Chinese National Reimbursement Drug List (NRDL) in 2020....
Autores principales: | Zhang, Donger, Li, Xia, Ding, Jing, Ke, Xiatong, Ding, Wenpei, Ren, Yinan, Xu, He, Li, Hongchao, Ma, Aixia, Tang, Wenxi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290415/ https://www.ncbi.nlm.nih.gov/pubmed/34295868 http://dx.doi.org/10.3389/fpubh.2021.670108 |
Ejemplares similares
-
Cognitive effects of adjunctive perampanel for partial‐onset seizures: A randomized trial
por: Meador, Kimford J., et al.
Publicado: (2016) -
The efficacy and safety of adjunctive perampanel for the treatment of refractory focal‐onset seizures in patients with epilepsy: A meta‐analysis
por: Li, Yiming, et al.
Publicado: (2022) -
Adjunctive perampanel for glioma-associated epilepsy()
por: Dunn-Pirio, Anastasie M., et al.
Publicado: (2018) -
Profile of perampanel and its potential in the treatment of partial onset seizures
por: Rheims, Sylvain, et al.
Publicado: (2013) -
Perampanel: What is its Place in the Management of Partial Onset Epilepsy?
por: Ledingham, David R. M., et al.
Publicado: (2013)